10-Q: Lineage Q3 2025: Clinical Progress, Increased Loss, New Deals

Lineage Cell Therapeutics reported a significant net loss in Q3 2025, driven by non-cash charges, while advancing its OpRegen and OPC1 clinical programs and securing a new collaboration for ReSonance.

Summary

• Net loss attributable to Lineage significantly increased to $64.38 million for the nine months ended September 30, 2025, from $15.34 million in the prior year.
• Total revenues for the nine months ended September 30, 2025, increased by 20% to $7.95 million, primarily due to a new research collaboration agreement with William Demant Invest 2 Aps (WDI).
• Operating expenses rose by 65% to $38.02 million, largely due to a $14.84 million non-cash impairment charge related to the abandoned VAC platform.
• Cash, cash equivalents, and marketable securities stood at $40.5 million as of September 30, 2025, which is believed to be sufficient for at least the next 12 months.
• Positive 36-month visual acuity results for OpRegen in geographic atrophy (GA) secondary to age-related macular degeneration (AMD) were presented in June 2025, showing durable improvements.
• Initiated the DOSED clinical study for OPC1 in spinal cord injuries (SCI), dosing the first chronic SCI participant in August 2025 with no significant safety events reported through 60 days post-treatment.
• Entered a research collaboration with WDI for ReSonance (ANP1) for hearing loss, with WDI funding up to $12 million in preclinical development costs over approximately three years.
• Warrant liabilities significantly increased to $45.17 million as of September 30, 2025, from $6.16 million at year-end 2024, primarily due to an increase in the common share price.

Sentiment

Score: 5

Explanation: The company shows strong clinical progress and new collaborations, which are positive for long-term potential. However, this is offset by a significant increase in net loss driven by non-cash charges, a substantial rise in warrant liabilities, and an ongoing legal dispute, indicating financial challenges and uncertainties.

Positives

• OpRegen Phase 1/2a clinical trial showed positive 36-month visual acuity results, with gains in Best Corrected Visual Acuity (BCVA) in Cohort 4 patients persisting through month 36 following subretinal administration.
• The mean change in BCVA was +9.0 ETDRS letters for patients completing 3-year follow-up with extensive OpRegen cell therapy coverage of atrophic areas (n=5).
• OpRegen received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) in September 2024.
• Initiated the DOSED clinical study for OPC1, including the first chronic SCI participants, with the first participant dosed in August 2025 and no significant safety events reported through sixty days post-treatment.
• Secured a new research collaboration agreement with William Demant Invest 2 Aps (WDI) for ReSonance (ANP1), with WDI funding up to $12 million in preclinical development costs over approximately three years.
• Demonstrated reproducible and scalable current Good Manufacturing Practice (cGMP) cell therapy production capability for OpRegen, OPC1, and ReSonance.
• Net cash used in operating activities decreased to $14.04 million for the nine months ended September 30, 2025, from $16.75 million in the prior year.

Negatives

• Net loss attributable to Lineage significantly increased to $64.38 million for the nine months ended September 30, 2025, compared to $15.34 million for the same period in 2024.
• Recorded a $14.84 million non-cash impairment charge in the second quarter of 2025 due to the abandonment of the VAC platform and its related research and development efforts.
• Warrant liabilities increased substantially to $45.17 million as of September 30, 2025, from $6.16 million at December 31, 2024, primarily driven by an increase in the company's common share price.
• Accumulated deficit grew to $467.85 million as of September 30, 2025.
• Total assets decreased to $89.64 million as of September 30, 2025, from $113.22 million at December 31, 2024.
• Total liabilities increased to $68.84 million as of September 30, 2025, from $36.21 million at December 31, 2024.

Risks

• The Israeli regional conflict and broader geopolitical conflicts could materially and adversely impact operations, including the Jerusalem manufacturing facility and employee availability, despite business continuity plans.
• Macroeconomic conditions such as inflation, high interest rates, slowed economic growth, and volatility in financial markets may adversely affect the business, financial condition, and ability to raise additional capital.
• Changes in the regulatory landscape, including potential reductions in FDA funding and staffing, could delay or limit the ability to obtain guidance and slow review times for clinical study applications.
• No assurances can be given that the company will be able to consistently manufacture clinical quantities of product candidates in accordance with cGMP or at a cost-effective or commercially viable scale.
• The outcome of the legal proceeding with Hadasit Bio-Holdings Ltd. (HBL) regarding the Intercompany Agreement is uncertain, with a third-party valuation firm reporting that the consideration paid by Lineage to CCN was insufficient.
• The company expects to continue incurring significant operating losses and will need substantial additional capital to fund operations, with no assurance that adequate capital will be available on favorable terms.
• The full cash exercise of outstanding OpRegen clinical milestone-linked warrants is not assured, potentially limiting expected proceeds.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it advances its product candidates. It believes current cash, cash equivalents, and marketable securities are sufficient to fund planned operations through at least the next 12 months. Future funding requirements will depend on research and development progress, changes to the scope and focus of those programs, changes in grant funding, and projection of future costs, revenues, and rates of expenditure. The company plans to leverage its manufacturing expertise to produce a cost-effective, scalable, and consistent supply of allogeneic cell transplant product candidates for itself and others, including for indications requiring large cell doses or with large patient populations.

Management Comments

• "We expect DOSED will enable future subsequent studies aimed to demonstrate OPC1's ability to impact functional outcomes."
• "We plan to leverage this expertise to produce a cost-effective, scalable, and consistent supply of allogeneic cell transplant product candidates for ourselves and others, including for indications requiring large cell doses or with large patient populations."
• "We believe that our $40.5 million in cash, cash equivalents and marketable securities at September 30, 2025, will be sufficient to fund our planned operations through at least twelve months from the issuance date of our condensed consolidated interim financial statements."
• "We believe we will meet our longer-term expected future cash requirements and obligations with our current cash and cash equivalents, milestone and other payments we expect to receive under our collaboration agreements, and proceeds we receive from sales of our common shares under our at-the-market offering program."

Industry Context

Lineage Cell Therapeutics operates in the highly specialized and capital-intensive clinical-stage biotechnology sector, focusing on allogeneic cell therapies. The company's progress with OpRegen for geographic atrophy and OPC1 for spinal cord injury aligns with broader industry trends towards regenerative medicine and advanced cell-based treatments for degenerative diseases and injuries. The collaboration with Roche/Genentech for OpRegen and WDI for ReSonance highlights the industry's increasing reliance on strategic partnerships to de-risk and accelerate development, especially for complex cell therapies requiring significant investment and specialized manufacturing capabilities. The emphasis on scalable, cost-effective manufacturing addresses a critical hurdle for commercialization in the cell therapy space.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Hadasit Bio-Holdings Ltd. (HBL), an approximately 5% shareholder of CCN, filed a motion for disclosure of documents to examine a potential derivative action related to an Intercompany Collaboration and License Agreement between Lineage and CCN.
• HBL alleges the Intercompany Agreement was an interested party transaction, not fairly priced, and exploited CCN's resources for Lineage's benefit.
• A third-party valuation firm delivered a report in June 2025 stating that the consideration paid by Lineage to CCN under the Intercompany Agreement was insufficient.
• The court extended the settlement deadline to January 4, 2026; if not settled by this date, a hearing will be held on HBL's motion.
• The likelihood of a material adverse effect on Lineage's consolidated results of operations, cash flows, or financial position from this proceeding is not estimable at this time, and no accrual for a contingent liability has been recorded.

Related Party Transactions

• In January 2025, Lineage sold 7,894,737 common shares and an accompanying warrant to purchase up to 7,894,737 common shares to Broadwood Partners, L.P., an affiliate of Neal Bradsher (a member of the board of directors), in the second closing of the November 2024 Registered Direct Offering (RDO).

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and warrant exercises, impact from increased net loss and warrant liabilities, potential upside from clinical progress and collaborations, and uncertainty from ongoing legal proceedings.
• Employees, particularly those at the Cell Cure Neurosciences Ltd. (CCN) facility in Jerusalem, Israel, have experienced temporary operational impacts due to the regional conflict, with some employees subject to military call-up.
• Customers and patients could benefit from the potential development of new cell therapies (OpRegen, OPC1, ReSonance) designed to address serious medical conditions.
• Creditors may note the increased total liabilities, but the company's cash position is stated to be sufficient for at least the next 12 months.
• Collaboration partners (Roche/Genentech, WDI) are seeing continued progress on their partnered programs, with WDI providing significant funding for ReSonance preclinical development.

Next Steps

• CIRM is expected to make a decision in December 2025 regarding Lineage's application for approximately $7.0 million in additional funding to support the OPC1 DOSED study.
• Negotiate terms for one or more separate clinical agreements with WDI for ReSonance (ANP1) after completing the preclinical phase.
• The court will hold a hearing on HBL's motion regarding the Intercompany Agreement if the matter is not settled by January 4, 2026.
• Continue the development of product candidates and seek regulatory approval.
• Seek additional capital through equity offerings, debt financings, government or other grant funding, or other third-party funding transactions, including potential strategic alliances and licensing or collaboration agreements, or structured financings such as royalty monetization transactions.

Key Dates

Recommendation

While Lineage Cell Therapeutics has demonstrated significant clinical progress with OpRegen's durable visual acuity improvements and the initiation of the OPC1 DOSED study, alongside a new collaboration for ReSonance, the financial results show a substantial increase in net loss, primarily due to non-cash impairment and warrant revaluation. The company's cash position is stated to be sufficient for 12 months, but future capital raises are anticipated. An ongoing legal dispute with a negative third-party valuation report adds uncertainty. Given the mixed bag of strong scientific advancements and notable financial challenges, a 'Hold' recommendation is appropriate for a seasoned investor, awaiting further clarity on financial stability and the resolution of legal matters, while acknowledging the long-term potential of its pipeline.

Keywords

Cell Therapy, Biotechnology, OpRegen, Geographic Atrophy, AMD, OPC1, Spinal Cord Injury, ReSonance, Auditory Neuropathy, Clinical Trials, SEC Filing, 10-Q, LCTX, Roche, Genentech, CIRM, WDI, Manufacturing, RMAT Designation, Financial Results, Net Loss, Warrant Liabilities, Capital Raise, Israel Conflict